rhinosinusitis%20-%20acute,%20bacterial
RHINOSINUSITIS - ACUTE, BACTERIAL
Acute bacterial rhinosinusitis is the mucosal inflammation of the nose and paransal sinuses caused by bacteria lasting >10 days for up to 4 weeks or symptoms worsening for 5-7 days and is <12 weeks with complete resolution of symptoms.
It is often preceded by a viral upper respiratory tract infection.
Signs and symptoms are nonspecific and typically difficult to differentiate from viral upper respiratory tract infection.
There is fever with nasal obstruction/congestion or anterior and/or posterior purulent drainage, with or without facial pressure/pain/fullness and reduction/loss of smell.
Streptococcus pneumoniae and unencapsulated strains of Haemophilus influenzae cause half of acute rhinosinusitis cases.

Otolaryngologist Referral

  • Reassure and educate the patient about the nature of URTI and ABRS and expected duration of illness
  • Encourage the patient to implement home self-care measures to provide relief of symptoms and prevent the occurrence of ABRS
  • Maintain adequate hydration by drinking 6-10 glasses of water/day to thin the mucus
  • Steamy baths: Inhaled steam (from a hot bath/shower) may loosen secretions
  • If necessary, increase humidity at home
  • Apply warm facial packs (eg warm wash cloth, hot water bottle) for 5-10 minutes ≥3 x/day to promote drainage of mucus and provide some localized relief
  • Adequate rest
  • Avoid irritants that affect sinuses eg cigarette smoke, extreme cool or dry air, pollution, swimming in contaminated water and barotrauma
  • Appropriate management of allergies and viral URTI (eg frequent handwashing)
  • There is little evidence on the efficacy of phytomedical preparations, immunomodulators and bacterial lysate preparations
  • There is no proven benefit to the use of mist, zinc salt lozenges, ascorbic acid, or echinacea
Treatment with Antibiotics
  • Educate the patient about worsening signs and symptoms that should prompt them to contact a physician 
  • It is important to counsel the patient on the use of the medications and its dosing schedule and the potential adverse effects
  • It is important to instruct the patient to complete the course of antibiotics
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 02 Oct 2018
Triple therapy with budesonide, glycopyrrolate, and formoterol in one metered dose inhaler (BGF MDI) appears effective and is well-tolerated in patients with symptomatic moderate-to-severe chronic obstructive pulmonary disease (COPD) irrespective of exacerbation history, the multicentre, phase III KRONOS* trial has shown.
Dr. Fanny Wai-San Ko, Dr. Wing-Ho Yip, 15 Aug 2018
Although a majority of patients can achieve good asthma control with the use of inhaled corticosteroid (ICS) and bronchodilators, some patients’ asthma remain uncontrolled despite the use of these medications.
Stephen Padilla, 14 Jan 2019
Overall, the risk of lung cancer is higher in former and current smokers with higher concentrations of high sensitivity C-reactive protein (hsCRP), according to a study. Additionally, circulating hsCRP is not associated with the risk of lung adenocarcinoma and may reflect a prediagnostic disease state rather than a causal risk for lung cancer.
20 Feb 2018
Dr Michael Lim, consultant of the Division of Paediatric Pulmonary and Sleep in National University Hospital, Singapore, shares his insights with Pearl Toh on diagnosing and managing paediatric asthma in the primary care setting.